Vaxcyte announced the completion of enrollment in its Phase 1/2 clinical study evaluating VAX-31, a 31-valent pneumococcal conjugate vaccine candidate designed to prevent invasive pneumococcal disease, in healthy adults aged 50 and older. Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 1/2 study in the third quarter of 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PCVX:
- Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
- Vaxcyte appoints Whitney Jones as Chief People Officer
- Vaxcyte Appoints Whitney Jones as Chief People Officer
- Needham ups Phathom target, adds to Conviction List as top 2024 pick
- Vaxcyte gives PCV franchise update, advances adult VAX-31 Phase 1/2 study